The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12624000062527
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
13/12/2023
Date registered
Help: Date registered
25/01/2024
Date last updated
Help: Date last updated
8/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
25/01/2024
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluate the effectiveness of the SAFE-T nursing care bundle in protecting skin from DEvice harm across the liFEspan iN Critical illnEss: The DEFENCE project
Scientific title
A hybrid type 2 effectiveness-implementation study with a sequential, multi-centre, incomplete stepped wedge cluster trial to evaluate the effectiveness of the SAFE-T nursing care bundle to prevent device related pressure injuries in ICU patients across the lifespan
Additional trial identifiers [1] 310836 0
Grant ID: APP2022546: Issuing authority: Australian Government (NH&MRC Partnership Scheme)
Universal Trial Number (UTN)
Trial acronym
DEFENCE
Related trial records

Health condition
Health condition(s) studied:
Device-related pressure injuries 332293 0
Condition category
Condition code
Skin 329007 329007 0 0
Other skin conditions
Injuries and Accidents 329008 329008 0 0
Other injuries and accidents
Public Health 329205 329205 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The SAFE-T Bundle is an evidence-based nursing care bundle comprising five elements to prevent medical device-related pressure injuries in critically ill patients. The SAFE-T Bundle provides guidance to ICU clinicians regarding selection and sizing of devices, assessment and protection of skin, device fixation and securement, repositioning of devices, and timely device removal. Site-specific implementation strategies, including education and training, will be developed through the Phase 1 implementation survey, workshops and site implementation meetings. The bundle elements remain consistent across sites but are tailored to the devices used, patient population and clinical practices at each ICU.
The SAFE-T Bundle consists of five elements:
1. Select and size the device: Device application should be based on direct clinical need, and devices should be appropriately sized and fitted to the patient.
2. Assess and protect the skin: The condition of the skin and mucous membranes under and around the device, including associated tubing and cords, should be assessed regularly as part of routine skin assessment (minimum 8-hourly). Appropriate measures should be used to protect areas at risk of pressure-related tissue damage.
3. Fix and secure the device: Devices should be fixed and secured to maintain patency and performance while minimising mechanical pressure and shear forces at the device-skin or device-tissue interface. Where appropriate, devices should be kept free within an orifice rather than creating pressure against surrounding tissues.
4. Evaluate and exchange the position of the device: Devices should be repositioned or rotated where possible to redistribute or offload pressure over different parts of the tissues, optimally at least 4-hourly where appropriate and depending on device type. Care should be taken to minimise gravitational pull of the device on the skin and other tissues.
5. Timely removal of devices: Removal of, or changing the location of, devices should be considered regularly (at least daily), with devices removed as soon as clinically possible.
The bundle applies to a broad range of medical devices, including devices used for breathing (endotracheal tubes, bite blocks, high-flow nasal prongs, face masks, nasal cannulae, CPAP and tracheostomy); feeding (nasogastric and orogastric tubes, PEG and jejunostomy); vascular access and other catheters (central lines, arterial lines, PICCs, ECMO, dialysis and peripheral intravenous catheters); monitoring probes (oxygen saturation probes, blood pressure cuffs, ECG dots and leads, temperature and glucose monitors, intracranial pressure monitoring probes and tubes); indwelling and suprapubic catheters; restraints and braces; bowel management systems; and other devices including DVT prophylaxis devices, epidurals, and cooling and warming blankets.
The SAFE-T Bundle will be delivered by ICU nursing staff as part of routine patient care. Site investigators and study champions will provide training, education and assistance to ICU clinicians during implementation. The implementation strategies will be informed by the Phase 1 implementation survey and workshops and further adapted through implementation meetings at each participating ICU.
The SAFE-T Bundle will be incorporated into routine nursing care at the bedside. Site investigators and study champions will support implementation through education, training, liaison with ICU clinicians and assistance with implementation of the five bundle elements. The implementation approach will be adapted to each ICU according to local barriers and enablers, devices used, patient population and existing clinical practices, while the five SAFE-T Bundle elements remain unchanged.
The SAFE-T Bundle will be introduced during a two-month transition period. The bundle will then be delivered as part of routine nursing care throughout the six-month intervention period. The bundle will subsequently be assessed during a one-month sustainability period following a three-month wash-out period. The individual bundle activities are incorporated into routine care at clinically appropriate intervals: skin assessment at a minimum of 8-hourly, repositioning or exchange of device position optimally at least 4-hourly where appropriate and device removal or relocation considered at least daily.
The intervention will be delivered in eight ICUs across five public hospitals in Queensland, comprising neonatal, paediatric and adult ICU settings. The participating ICUs are the Mater Mothers Hospital Neonatal ICU; Queensland Children's Hospital Paediatric ICU; Royal Brisbane and Women's Hospital Neonatal ICU and Adult ICU; The Prince Charles Hospital Adult ICU; and the Neonatal, Paediatric and Adult ICUs at Townsville University Hospital.
Adherence to the SAFE-T Bundle will be monitored by research nurses through direct observation of nursing care. Compliance with each of the five SAFE-T Bundle elements will be recorded using yes/no measures. Compliance will be assessed during the intervention and sustainability periods. Sustainability of bundle implementation will be assessed during the one-month sustainability period following the three-month wash-out period. Nursing ICU staff will also be surveyed regarding the acceptability, appropriateness, feasibility and sustainability of the intervention.
Intervention code [1] 327580 0
Prevention
Description of the comparator or control
A sequential, multi-centre, incomplete stepped-wedge cluster randomised control trial design will be used to evaluate the SAFE-T care bundle of evidence-based clinical practices compared with standard nursing care. Every cluster ICU will provide a 4-month control period data on device-related pressure injuries. Standard nursing care will be the practices and procedures used by nurses in each separate ICU to prevent and treat device related pressure injuries.
Control group
Active

Outcomes
Primary outcome [1] 336805 0
Incidence of device-related pressure injury during ICU admission in the intervention group compared to control /usual care.
Timepoint [1] 336805 0
During the control, transition and intervention periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Secondary outcome [1] 429723 0
Incidence rate of new ICU device-related pressure injuries per 1,000 patient-days in the intervention group compared with control/usual care
Timepoint [1] 429723 0
During the control, transition and intervention periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Secondary outcome [2] 429725 0
Time to new ICU device-related pressure injury development in the intervention group compared to control /usual care.
Timepoint [2] 429725 0
During the control, transition and intervention periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Secondary outcome [3] 429726 0
Number of new ICU device related pressure injuries per patient in the intervention group compared to control /usual care.
Timepoint [3] 429726 0
During the control, transition and intervention periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Secondary outcome [4] 429727 0
Translational process evaluation (80% bundle adherence)
Timepoint [4] 429727 0
Data collection will occur during all periods of the trial except for washout with weekly fidelity audits conducted throughout.
Secondary outcome [5] 429728 0
Cost effectiveness of the SAFE-T bundle care (intervention period) based on health economics analysis.
Timepoint [5] 429728 0
All three measures will be collected daily in the final month of the intervention period.
Secondary outcome [6] 429732 0
Proportion of patients with new ICU device-related pressure injuries during the sustainability period compared to the intervention period.
Timepoint [6] 429732 0
During the intervention and sustainability periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death
Secondary outcome [7] 430466 0
The type/stage of new ICU device-related pressure injuries
Timepoint [7] 430466 0
At all patient data collection periods - Control, Transition, Intervention and Sustainability periods in the step-wedge trial. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Secondary outcome [8] 430482 0
Implementation outcomes of acceptability [the perception that the SAFE-T bundle is agreeable or satisfactory]
Timepoint [8] 430482 0
The survey will be conducted in the sustainability period - 4th month post intervention period.
Secondary outcome [9] 430483 0
Implementation outcomes of appropriateness [the perceived fit or compatibility of the SAFE-T bundle to address device related pressure injuries]
Timepoint [9] 430483 0
The survey will be conducted in the sustainability period - 4th month post intervention period.
Secondary outcome [10] 430484 0
Implementation outcomes of feasibility [the extent to which the SAFE-T bundle can be successfully used by each partner site]
Timepoint [10] 430484 0
The survey will be conducted in the sustainability period - 4th month post intervention period.
Secondary outcome [11] 430485 0
Implementation outcomes of sustainability [normalization of complexed interventions]
Timepoint [11] 430485 0
The survey will be conducted in the sustainability period - 4th month post intervention period.
Secondary outcome [12] 430488 0
Willingness to pay to avoid device-related pressure injury (survey measure)
Timepoint [12] 430488 0
This survey will be conducted during the control and transition periods prior to implementation of the SAFE-T bundle at each site.
Secondary outcome [13] 430489 0
Implementation barriers to SAFE-T bundle uptake (CFIR-informed determinants)
Timepoint [13] 430489 0
Survey to be completed in the Control period before the workshop.
Secondary outcome [14] 430490 0
Implementation Workshops to prioritize the recommended implementation strategies
Timepoint [14] 430490 0
Workshops to be completed in the Control period
Secondary outcome [15] 430494 0
Cost effectiveness Evaluation (Composite measure)
Timepoint [15] 430494 0
For each element of this composite measure 1) Phase 1 before the start of any ICU control period 2) Final month (6th month) of the Intervention period 3) Both control and intervention periods
Secondary outcome [16] 467590 0
Implementation facilitators to SAFE-T bundle uptake (CFIR-informed determinants)
Timepoint [16] 467590 0
Survey to be completed in the Control period before the workshop.

Eligibility
Key inclusion criteria
Admitted patients have at least one therapeutic device
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Patient has not been previously enrolled in the study

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The unit of randomisation is the 'cluster' not the recruited patient. The clusters (8 ICUs) will be randomised using computer software to a unique start sequence in the stepped wedge design. Each cluster will start in the control phase and cross over to intervention conditions. Sequence generation will be conducted by the Chief Investigator statistician.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



The people analysing the results/data
Intervention assignment
Other
Other design features
Hybrid type 2 effectiveness-implementation trial using a sequential, multi-centre, incomplete, stepped-wedge, cluster randomised trial design
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Poisson generalised linear mixed-effects models will be used to analyse the primary outcome, with appropriate models applied to secondary outcomes depending on outcome type. The primary outcome of DRPI incidence between control and intervention periods will be analysed using a Poisson mixed-effects model with patient-days of observation included as an offset to account for variation in time at risk. Models will include fixed effects for time, random cluster effects, and random cluster by time effects. The correlation structure for the random cluster by time interaction will allow two-period decay, enabling correlation within the same measurement period to differ from that in different measurement periods. Results will be presented as incidence rate ratios (IRRs) with 95% confidence intervals. Negative Binomial will be used if the data are over dispersed. Time to DRPI will also be examined using mixed effects Cox regression models with hazard ratios and 95% confidence intervals reported. Assumptions of all models will be examined using residuals. Models will be adjusted for important clinical and demographic factors. The primary analysis of all endpoints will be ‘intention-to-treat’ (ITT), with ‘per protocol’ (PP) analyses assessing the effect of protocol compliance. Protocol compliance and performance (dose response) will be assessed by considering percentage compliance (yes/no) for the five components of the bundle, with compliance categorised into groups of increasing gradients from no compliance (0%) to full compliance (100%) and included as a factor in the model. Missing values will not be imputed but will be considered through the mixed modelling approach, which assumes a missing at random mechanism. Sensitivity analyses will consider models assuming missing not at random mechanism, such as shared parameter models. Two-tailed p-values of <0.05 will be considered significant.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 25928 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [2] 25929 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [3] 25930 0
Mater Mother's Hospital - South Brisbane
Recruitment hospital [4] 25931 0
The Prince Charles Hospital - Chermside
Recruitment hospital [5] 25932 0
Townsville University Hospital - Douglas
Recruitment postcode(s) [1] 41763 0
4029 - Herston
Recruitment postcode(s) [2] 41764 0
4101 - South Brisbane
Recruitment postcode(s) [3] 41765 0
4032 - Chermside
Recruitment postcode(s) [4] 41766 0
4814 - Douglas

Funding & Sponsors
Funding source category [1] 315081 0
Government body
Name [1] 315081 0
National Health and Medical Research Council (NHMRC)
Country [1] 315081 0
Australia
Funding source category [2] 315412 0
Hospital
Name [2] 315412 0
Townsville University Hospital
Country [2] 315412 0
Australia
Funding source category [3] 315413 0
Hospital
Name [3] 315413 0
Royal Brisbane and Women's Hospital
Country [3] 315413 0
Australia
Funding source category [4] 315423 0
Hospital
Name [4] 315423 0
The Prince Charles Hospital
Country [4] 315423 0
Australia
Primary sponsor type
University
Name
The University of Queensland
Address
University of Queensland ST LUCIA QLD 4072
Country
Australia
Secondary sponsor category [1] 317476 0
None
Name [1] 317476 0
Address [1] 317476 0
Country [1] 317476 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 314029 0
Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee [EC00175]
Ethics committee address [1] 314029 0
Ethics committee country [1] 314029 0
Australia
Date submitted for ethics approval [1] 314029 0
09/10/2023
Approval date [1] 314029 0
08/11/2023
Ethics approval number [1] 314029 0
62 Graham Street, South Brisbane QLD 4101

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 130174 0
Prof Amanda Ullman
Address 130174 0
School of Nursing, Midwifery and Social Work, Level 3, Chamberlain Building (35), University of Queensland, St Lucia, 4072
Country 130174 0
Australia
Phone 130174 0
+61 7 3365 2068
Fax 130174 0
Email 130174 0
Contact person for public queries
Name 130175 0
Amanda Ullman
Address 130175 0
School of Nursing, Midwifery and Social Work, Level 3, Chamberlain Building (35), University of Queensland, St Lucia, 4072
Country 130175 0
Australia
Phone 130175 0
+61 7 3365 2068
Fax 130175 0
Email 130175 0
Contact person for scientific queries
Name 130176 0
Amanda Ullman
Address 130176 0
School of Nursing, Midwifery and Social Work, Level 3, Chamberlain Building (35), University of Queensland, St Lucia, 4072
Country 130176 0
Australia
Phone 130176 0
+61 7 3365 2068
Fax 130176 0
Email 130176 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual participant data will not be shared. The outcomes of the trial will share with the public via peer-reviewed journal publications, presentations and various guidelines.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.